Pluri Inc's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 169/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 12.00.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Pluri Inc's Score
Industry at a Glance
Industry Ranking
169 / 404
Overall Ranking
300 / 4582
Industry
Biotechnology & Medical Research
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
1
analysts
Buy
Current Rating
12.000
Target Price
+283.39%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Pluri Inc Highlights
StrengthsRisks
Pluri Inc., formerly known as Pluristem Therapeutics Inc., is an Israel-headquartered company engaged in the research and provision of cell-based products directed for a range of industries. The Company is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Company are used for the pharmaceutical industry as well as for food technology, agriculture technology, and cell-based materials. In the pharmaceutical sector, the Company's preclinical and clinical programs explore multiple therapeutic areas such as vascular disease, inflammation-related conditions, muscle injuries, and hematological disorders. In the food sector, the Firm produces cultivated meat, cultivated fish, and seafood, as well as plant-based products. In agriculture, the Company develops alternative farming methods. The Company has a portfolio of over 140 granted patents in approximately 52 countries.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 365.51% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 1.34M.
Fairly Valued
The company’s latest PE is -1.08, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 1.60M shares, increasing 1.49% quarter-over-quarter.
Pluri Inc., formerly known as Pluristem Therapeutics Inc., is an Israel-headquartered company engaged in the research and provision of cell-based products directed for a range of industries. The Company is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Company are used for the pharmaceutical industry as well as for food technology, agriculture technology, and cell-based materials. In the pharmaceutical sector, the Company's preclinical and clinical programs explore multiple therapeutic areas such as vascular disease, inflammation-related conditions, muscle injuries, and hematological disorders. In the food sector, the Firm produces cultivated meat, cultivated fish, and seafood, as well as plant-based products. In agriculture, the Company develops alternative farming methods. The Company has a portfolio of over 140 granted patents in approximately 52 countries.
Ticker SymbolPLUR
CompanyPluri Inc
CEOYanay (Yaky)
Websitehttps://pluri-biotech.com/
FAQs
What is the current price of Pluri Inc (PLUR)?
The current price of Pluri Inc (PLUR) is 3.460.
What is the symbol of Pluri Inc?
The ticker symbol of Pluri Inc is PLUR.
What is the 52-week high of Pluri Inc?
The 52-week high of Pluri Inc is 7.130.
What is the 52-week low of Pluri Inc?
The 52-week low of Pluri Inc is 2.820.
What is the market capitalization of Pluri Inc?
The market capitalization of Pluri Inc is 28.24M.
What is the net income of Pluri Inc?
The net income of Pluri Inc is -22.58M.
Is Pluri Inc (PLUR) currently rated as Buy, Hold, or Sell?
According to analysts, Pluri Inc (PLUR) has an overall rating of Buy, with a price target of 12.000.
What is the Earnings Per Share (EPS TTM) of Pluri Inc (PLUR)?
The Earnings Per Share (EPS TTM) of Pluri Inc (PLUR) is -3.137.